Ivonescimab Meets HARMONi-2 Overall-Survival Endpoint

Companies: Akeso / Summit Therapeutics · Drug: Ivonescimab · Trial: HARMONi-2 (AK112-303, Phase III) · Indication: First-Line PD-L1-Positive Advanced NSCLC · Date: September 3, 2026 Summary Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind…